… Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm … of Imatinib initially as
salvage therapy in 2001 and subsequently as front line therapy revolutionized CML therapy, …

… IRIS, the long-term outcomes in imatinib-treated patients that we describe here confirm …
could be evaluated. The estimated overall survival rate at 10 years with first-line imatinib therapy …

… four treatment arms: imatinib 400 mg once daily; imatinib 600 … is: how should we advise a
patient who does not meet the 3-… there are no data indicating this will alter long-term outcome. …

… For practical purpose, a term frequently used is operational or functional cure. Can we
use the term when someone continues treatment with no evidence of detectable disease? …

… Imatinib, the first BCR/ABL kinase inhibitor approved for the treatment of chronic myeloid
leukemia (CML), has changed the long-term outcome of patients affected by this disease. The …

… , S.; Iacobucci, I.; De Vivo, A.; Testoni, N.; Castagnetti, F.; Gugliotta, G.; et al. Effects and
outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid …

… The objective of chronic myeloid leukemia treatment is to remove … of every sick cell, yet
treatment can accomplish a long haul … (Chronic) stage interminable myelogenous leukemia (CML) …

… The first trial with imatinib, a phase I study with poor risk CML patients, started in 1998. The
stunning results convinced even skeptics that further studies were indicated. In 1999, a group …

… June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for patients …

… Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of one
to … to one of four treatment arms (imatinib 400 mg once daily, imatinib 600 mg once daily, …